• Quick Summary
  • MOA
  • Efficacy
    • Fracture
    • Bone Mineral Density
    • Improved Bone Quality
  • Safety
    • Most Common Side Effects
    • Other Safety Information
  • Dosing & Administration
  • Resources
    • Download Patient Guide
    • Access Key Organizations
Physician's Main :: Resources :: Access Key Organizations

Access key organizations

Below are links to organizations providing information about osteoporosis and women’s health issues.

The American College of Obstetricians and Gynecologists (ACOG)

Food and Drug Administration/US Department of Health and Human Services (FDA/DHHS)

National Institute on Aging/U.S. National Institutes of Health (NIA/NIH)

National Osteoporosis Foundation (NOF)

National Women’s Health Resource Center (NWHRC)

The North American Menopause Society (NAMS)

The Office on Women’s Health/U.S. Department of Health and Human Services (OWH/OHHS)








 
HOME | PATIENT INFORMATION LEAFLET | PRESCRIBING INFORMATION
CORPORATE | PRIVACY POLICY | LEGAL NOTICES


IMPORTANT SAFETY INFORMATION
Indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause with low bone mass relative to healthy premenopausal women. Recommended in conjunction with adequate calcium and vitamin D intake. The most common adverse events were rhinitis, other nasal symptoms, back pain, arthralgia, epistaxis, and headache. Periodic nasal examinations are recommended; if nasal ulceration occurs, discontinue treatment until healed. Because calcitonin-salmon is a protein, the possibility of systemic allergic reaction exists. Please refer to full prescribing information.


1-800-654-2299 www.upsher-smith.com
©2009 Upsher-Smith Laboratories, Inc., Maple Grove, MN 55369